EMA has launched a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.
In a May 6, 2019 press release, the European Medicines Agency (EMA) announced the launch of a social media campaign aimed at highlighting how the agency and its network maintain safety and efficacy of medicines available in Europe.
Through a series of info-cards shared via EMA’s LinkedIn and Twitter accounts, the agency describes the added value of European cooperation in keeping medicines safe. The visuals demonstrate how various actions such as pooling resources to monitor and analyse safety information across the region, raising safety standards, and allowing patients to directly report side effects and identify legally operating online pharmacies and retailers, all aid in keeping medicines safe.
As a key priority for EMA, the European Commission, and the network of national authorities that provide the agency with scientific expertise for medicines regulation, the agency encourages everyone to support the campaign through sharing the info-cards on social media themselves.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
2 Commerce Drive
Cranbury, NJ 08512